Fundraising Fox
Syndax Pharmaceuticals
NASDAQ: SNDXWaltham, US · Incorporated in Delaware · 333 employees on LinkedIn · 13 known investors
Find your way into Syndax Pharmaceuticals
Sign up to see every warm intro you have to Syndax Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Syndax Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.
Founders & leadership
Board
Investors · 13
How we know: Aisling Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: ATEM Capital Fund's portfolio page · Not right? Tell us
How we know: Avoro Capital Advisors's portfolio page · Not right? Tell us
How we know: Foresite Capital's portfolio page · Not right? Tell us
How we know: Pappas Capital's portfolio page · Not right? Tell us
How we know: Sofinnova Ventures's portfolio page · Not right? Tell us
How we know: venBio Partners's portfolio page · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: the S-1 prospectus · a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$93.2M disclosed across 5 rounds · 2014–2015
▶$61.3MraisedAug 2015 · 19 investors · PharmaceuticalsRule 506(b)
- Dennis PodlesakDirector
- Fabrice Egros, Ph.D.Director
- Michael MetzgerExecutive Officer
- Kim Kamdar, Ph.DDirector
- Luke Evnin, Ph.D.Director
- Ivor Royston, M.D.Director
- George W Sledge, Jr., M.D.Director
- John PalliesExecutive Officer
- Richard P SheaDirector
- Henry ChenDirector
- Briggs Morrison, M.D.Executive Officer, Director
- Offering amount
- $61.3M
- Amount sold
- $61.3M
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$24MraisedJun 2015 · 12 investors · PharmaceuticalsRule 506(b)
- George W Sledge, Jr. M.D.Director
- Richard P SheaDirector
- Ivor RoystonDirector
- Fabrice Egros, Ph.D.Director
- Luke Evnin, Ph.D.Director
- Henry ChenDirector
- Michael MetzgerExecutive Officer
- John PalliesExecutive Officer
- Dennis PodlesakDirector
- Kim Kamdar, Ph.DDirector
- Offering amount
- $45.2M
- Amount sold
- $24M
- First sale
- Jun 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.9MraisedSep 2014 · 10 investors · PharmaceuticalsRule 506(b)
- Fabrice Egros, Ph.D.Director
- George W Sledge, Jr. M.D.Director
- Arlene MorrisExecutive Officer, Director
- John PalliesExecutive Officer
- Dennis PodlesakDirector
- Kim Kamdar, Ph.DDirector
- Ivor RoystonDirector
- Luke Evnin, Ph.D.Director
- Richard P SheaDirector
- Offering amount
- $5M
- Amount sold
- $4.9M
- First sale
- Sep 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.7MraisedFeb 2014 · 3 investors · PharmaceuticalsRule 506(b)
- Dennis PodlesakDirector
- Ivor RoystonDirector
- John PalliesExecutive Officer
- Luke Evnin, Ph.D.Director
- George W Sledge, Jr. M.D.Director
- Fabrice Egros, Ph.D.Director
- Arlene MorrisExecutive Officer, Director
- Richard P SheaDirector
- Kim Kamdar, Ph.DDirector
- Offering amount
- $1.7M
- Amount sold
- $1.7M
- First sale
- Feb 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.3MraisedFeb 2014 · 4 investors · PharmaceuticalsRule 506(b)
- Dennis PodlesakDirector
- Luke Evnin, Ph.D.Director
- Ivor RoystonDirector
- Arlene MorrisExecutive Officer, Director
- Kim Kamdar, Ph.DDirector
- Fabrice Egros, Ph.D.Director
- John PalliesExecutive Officer
- Richard P SheaDirector
- Offering amount
- $1.3M
- Amount sold
- $1.3M
- First sale
- Jan 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
2 people who came through Syndax Pharmaceuticals went on to found or lead other companies.
Frequently asked questions
- What does Syndax Pharmaceuticals do?
- Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.
- Who are Syndax Pharmaceuticals's investors?
- Syndax Pharmaceuticals's investors include Aisling Capital, ATEM Capital Fund, Avoro Capital Advisors, BioBrit, Delos Capital, EcoR1 Capital, Foresite Capital, Pappas Capital and 5 more.
- How much funding has Syndax Pharmaceuticals raised?
- Syndax Pharmaceuticals has disclosed $93.2M raised across 5 rounds.
- Where is Syndax Pharmaceuticals headquartered?
- Syndax Pharmaceuticals is headquartered in Waltham, US.